Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SSUMY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SSUMY and 80,000+ other tickers.
See exactly how SSUMY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SSUMY and 80,000+ other tickers.
Sumitomo Corporation operates as a global, diversified trading entity with extensive commercial activities spanning various sectors worldwide. Its comprehensive operations are structured into six key divisions: Metal Products; Transportation & Construction Systems; Infrastructure; Media & Digital; Living Related & Real Estate; and Mineral Resources, Energy, Chemical & Electronics. The company's involvement in the Metal Products segment includes the distribution of steel sheets and tubular goods. Its Transportation & Construction Systems division oversees the entire lifecycle of ships…
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis pigmentosa (RP) has undergone subretinal implantation. DSP-3077 is an investigative regenerative cell therapy that leverages allogeneic retinal sheets derived from induced pluripotent stem (iPS) cells. This Phase 1/2a, open-label, single-arm, uncontrolled, dose-escalation study (NCT06891885) is evaluating tw.
Sumitomo (SSUMY) could produce exceptional returns because of its solid growth attributes.
Investors interested in Diversified Operations stocks are likely familiar with Sumitomo Corp. (SSUMY) and Honeywell International Inc. (HON). But which of these two stocks presents investors with the better value opportunity right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors interested in Diversified Operations stocks are likely familiar with Sumitomo Corp. (SSUMY) and Honeywell International Inc. (HON). But which of these two stocks presents investors with the better value opportunity right now?